A semi-parametric approach for the quantitative analysis of magnetic resonance (MR) spectra is proposed and an uncertainty analysis is given. Single resonances are described by parametric models or by parametrized in vitro spectra and the baseline is determined nonparametrically by regularization. By viewing baseline estimation in a reproducing kernel Hilbert space, an explicit parametric solution for the baseline is derived. A Bayesian point of view is adopted to derive uncertainties, and the many parameters associated with the baseline solution are treated as nuisance parameters. The derived uncertainties formally reduce to Cramé r-Rao lower bounds for the parametric part of the model in the case of a vanishing baseline.The proposed uncertainty calculation was applied to simulated and measured MR spectra and the results were compared to Cramé r-Rao lower bounds derived after the nonparametrically estimated baselines were subtracted from the spectra. In particular, for high SNR and strong baseline contributions the proposed procedure yields a more appropriate characterization of the accuracy of parameter estimates than Cramé r-Rao lower bounds, which tend to overestimate accuracy. Accurate quantitative analysis of in vivo 1 H magnetic resonance spectra is a challenging task and has been the subject of research for a long time; see (1-3) for reviews. In addition to technical advances, such as higher field strength (4) and novel pulse sequences (5), the development of sophisticated quantification approaches (6 -16) has greatly contributed to establishing magnetic resonance spectroscopy (MRS) as a noninvasive tool for medical diagnosis and biochemical analysis. Further improvement of quantification methods is still a topic of interest, and to date a wide variety of methods are in use. Consequently, considerable effort has been undertaken in comparing different approaches of spectrum analysis (17)(18)(19)(20).Typically, parametric models including (parametrized) in vitro spectra are utilized for quantitative analysis of magnetic resonance (MR) spectra. Determination of the unknown MRS parameters is usually done by (nonlinear) least-squares fitting, either in the time or in the frequency domain. A serious difficulty arises-in particular when analyzing spectra acquired at short echo times (TE)-due to the presence of baseline contributions caused by residual water and macromolecules. Generally, no parametric model is available for these baseline contributions, but they can be assumed to be smooth in the frequency domain. Several methods have been proposed for dealing with this task; e.g., successful baseline treatment has been carried out by spline approximation (7) and application of wavelets (12), but incorporation of measured baselines has also been suggested (4,13,14).Characterizing the accuracies of calculated MRS parameter estimates is an important part of quantitative analysis, and reliable uncertainty calculation is mandatory for assessing or comparing individual results. Usually, accuracies of MRS parameter e...

To assess the applicability of magnetic resonance spectroscopy (MRS) for long-term follow-up of neurological diseases a longitudinal 1H-MRS study at 3 T was carried out on ten patients having relapsing-remitting multiple sclerosis (MS) who, after baseline examination, received interferon-beta (IFN) 1b. At 8-20 examinations within up to 34 months absolute concentrations of N-acetylaspartate (NAA), total creatine (tG), and choline-containing compounds (tCho) were determined in a large non-enhancing lesion and contralateral normal appearing white matter (NAWM). MR spectra were analyzed using a novel time domain-frequency domain method including non-parametric background characterization. For comparison at baseline, ten healthy controls were examined. The concentrations of tCho and tCr were found to be higher in MS brain than in control brain. Besides a non-significantly lower NAA concentration in lesions there were no concentration differences between lesions and NAWM. Over the follow-up period the measured metabolite concentrations exhibited a high variability. Most concentrations remained within this scatter, and statistical tests revealed significant fluctuations in the levels of metabolites in one case only. This stability of the metabolite concentrations over time might result from IFN therapy as for the spontaneous course of relapsing-remitting MS decreasing metabolite (NAA/tCr) ratios have been reported. The results further suggest that future treatment trials intending to use metabolite concentrations as a secondary outcome indicator use even longer observation periods and, besides group analysis of large cohorts, investigate the time behavior of selected single cases. The biochemical abnormalities found in NAWM emphasize the importance of analyzing both lesion and NAWM.

No abstract

No abstract

No abstract